CHA₂DS₂-VASc Score Calculator
CHA₂DS₂-VASc score calculator. The gold-standard atrial fibrillation stroke risk stratification used in every cardiology unit + emergency department globally. Educational only.
CHA₂DS₂-VASc Score Calculator
Please tick the acknowledgement above before calculating.
Score components
| Factor | Points |
|---|
How to use the CHA₂DS₂-VASc calculator
Confirm AFib diagnosis first
CHA₂DS₂-VASc applies to patients with atrial fibrillation or atrial flutter — both paroxysmal (intermittent) and persistent forms. It does NOT apply to patients in normal sinus rhythm. If you have not been formally diagnosed with AFib by a physician (ECG/Holter monitor), this score doesn't apply to you.
Enter age + sex
Age affects scoring: 65-74 = 1 point, ≥75 = 2 points. Female sex = 1 point (added in the 2010 update, hence the "-VASc"). Note: ESC 2024 + AHA/ACC 2023 guidelines now suggest female sex alone (score = 1 because of sex only) does NOT warrant anticoagulation.
Check applicable risk factors
Tick the boxes for: CHF history (any documented LV dysfunction), hypertension (on treatment OR untreated SBP > 140 / DBP > 90), diabetes, prior stroke/TIA/thromboembolism, vascular disease (prior MI, peripheral artery disease, or aortic plaque on imaging). Be thorough — missing a factor underestimates true risk.
Acknowledge the disclaimer
This is a clinical decision tool used by physicians, not a substitute for medical evaluation. Tick the acknowledgement checkbox to confirm understanding.
Discuss with your cardiologist
Score 0 (or 1 due to sex only): no anticoagulation. Score 1 (other): consider; shared decision-making. Score ≥ 2 (≥ 3 in women): anticoagulation strongly recommended. First-line: DOACs (apixaban, rivaroxaban, dabigatran, edoxaban). Warfarin alternative when DOACs contraindicated. Discuss bleeding risk (HAS-BLED score) as the counterweight.
CHA₂DS₂-VASc — the score every cardiology unit lives by
Atrial fibrillation (AFib) is the most common sustained cardiac arrhythmia, affecting ~38 million people globally. The clinical danger isn\'t the rhythm itself but the 5-fold elevated stroke risk it creates — fibrillating atria pool blood that can clot and embolise to the brain. Anticoagulation reduces stroke risk by ~64% but adds bleeding risk. The clinical question for every newly-diagnosed AFib patient: is anticoagulation worth it for this individual? The answer is computed via the CHA₂DS₂-VASc score, published by Lip et al in Chest 2010 — refining the older CHADS₂ score. It\'s used in every cardiology unit + emergency department globally; ESC, AHA/ACC, NICE guidelines all reference it. CHA₂DS₂-VASc is one of the most-used clinical decision tools in medicine.
How the score works
The acronym encodes 8 risk factors. C — congestive heart failure (1 pt). H — hypertension (1 pt). A₂ — age ≥ 75 (2 pts, hence the subscript). D — diabetes (1 pt). S₂ — prior stroke/TIA/thromboembolism (2 pts). V — vascular disease (1 pt). A — age 65-74 (1 pt). Sc — sex category female (1 pt). Maximum score 9. Annual stroke risk increases approximately linearly: score 0 = 0.2%, score 2 = 2.2%, score 5 = 7.2%, score 9 = 12.2% per year (Friberg et al, Eur Heart J 2012, Swedish AFib registry). The clinical action: anticoagulate at score ≥ 2 (men) or ≥ 3 (women).
CHA₂DS₂-VASc has prevented an estimated millions of strokes globally since 2010. Patients identified as high-risk and put on DOACs are 64% less likely to stroke than unanticoagulated equivalents.
The DOAC era
Before 2010, warfarin was the only oral anticoagulant — effective but inconvenient (INR monitoring, dietary restrictions, drug interactions). DOACs (Direct Oral Anticoagulants): apixaban (Eliquis), rivaroxaban (Xarelto), dabigatran (Pradaxa), edoxaban (Savaysa). All are at least as effective as warfarin for AFib stroke prevention with reduced major bleeding (especially intracranial hemorrhage). Apixaban has the best safety profile in head-to-head studies. ESC 2024 + AHA/ACC 2023 guidelines recommend DOACs as first-line over warfarin for AFib stroke prevention in most patients.
ASEAN AFib + anticoagulation
AFib prevalence in ASEAN is rising rapidly: Singapore + Hong Kong now match Western prevalence (~2-3%), Indonesia + Vietnam catching up. Asian-specific risk modifiers: lower body weight, higher intracranial hemorrhage risk on warfarin → DOACs particularly favored. DOAC access varies: Singapore + Hong Kong + Malaysia have full DOAC availability. Indonesia + Vietnam: more limited, often patients still on warfarin. The CHA₂DS₂-VASc score is universal — same algorithm, same thresholds, applied identically across ASEAN cardiology practices.
10 Things to Know About CHA₂DS₂-VASc
Published 2010 by Lip et al in Chest. Refinement of older CHADS₂ (2001).
Max score: 9 points. Annual stroke risk rises from 0.2% (score 0) to ~12% (score 9).
Threshold for anticoagulation: ≥2 men, ≥3 women. ESC 2024 + AHA/ACC 2023 agreement.
"-VASc" added Vascular disease + Age 65-74 + Sex category. Improved discrimination over original CHADS₂.
Female sex alone (score = 1 in a 60-yo female with no factors) NOT indication for anticoagulation per recent guidelines.
DOACs first-line over warfarin: apixaban, rivaroxaban, dabigatran, edoxaban. 64% stroke reduction.
Paired with HAS-BLED score for bleeding risk — provides counterweight to anticoagulation decision.
Validated across multiple international cohorts: Swedish, Danish, Taiwanese, Japanese, US, ASEAN.
Used for both paroxysmal and persistent AFib. Even rare episodes of AFib increase stroke risk.
Apixaban (Eliquis) has the best safety profile in head-to-head DOAC trials — first-line in 2026 practice.
Frequently asked questions
-
CHADS₂ (2001): 5 factors, max 6 points. CHA₂DS₂-VASc (2010): adds vascular disease, age 65-74, female sex — max 9 points. The newer score identifies more low-risk patients accurately (those scoring 0 truly have very low stroke risk and don\'t need anticoagulation). All current guidelines use CHA₂DS₂-VASc, not CHADS₂.
-
Lip et al observed in their 2010 data that AFib women had ~1.6× the stroke rate of AFib men at the same risk profile. Added as a separate point. BUT — subsequent analysis showed female sex alone (in absence of other factors) doesn\'t meaningfully elevate stroke risk to warrant anticoagulation. Current ESC 2024 + AHA/ACC 2023: a 65-yo female with no other factors (score = 1 from sex alone) does NOT need anticoagulation. Anticoagulation kicks in when she\'s already 2+ from non-sex factors.
-
Yes. CHA₂DS₂-VASc applies to ALL forms of AFib — paroxysmal (intermittent), persistent (lasts >7 days), permanent. Even brief AFib episodes (minutes) increase stroke risk. Patients with very rare paroxysmal AFib (annual single episode) are sometimes risk-stratified more leniently in practice, but guidelines apply the score uniformly.
-
Computed separately via the HAS-BLED score (Hypertension, Abnormal liver/renal function, Stroke, Bleeding history, Labile INR, Elderly, Drugs/alcohol). Score 0-2: low bleed risk. Score 3+: high bleed risk. Key insight: high HAS-BLED does NOT contraindicate anticoagulation — it identifies modifiable risk factors (BP control, alcohol reduction). Most patients with high CHA₂DS₂-VASc + high HAS-BLED still benefit from anticoagulation. Discuss with cardiologist.
-
Apixaban (Eliquis) has the best safety profile in head-to-head trials — lowest major bleeding, lowest intracranial hemorrhage. Rivaroxaban (Xarelto): once-daily convenience. Dabigatran (Pradaxa): reversal agent (idarucizumab) widely available. Edoxaban (Savaysa): once-daily, simpler dosing. Choice depends on: renal function (apixaban + rivaroxaban have less renal clearance issues), age (apixaban preferred in elderly), GI bleeding history (apixaban preferred), cost/insurance coverage. Discuss with your cardiologist.
-
Self-screening AFib (via Apple Watch, KardiaMobile, etc.) is increasingly common. If a smartwatch flags AFib, see a physician for ECG confirmation. If confirmed, computing CHA₂DS₂-VASc yourself can help you have an informed conversation about anticoagulation. But the FINAL decision (whether to anticoagulate, which DOAC, when to start) is made between you and your cardiologist.
-
Not necessarily. Even after successful ablation (restoration of normal rhythm), stroke risk may remain elevated. Many cardiologists continue anticoagulation post-ablation in patients with CHA₂DS₂-VASc ≥ 2, especially within the first 3-6 months. Some longer-term studies suggest reduced risk after ablation but data is evolving. Individual decision with your electrophysiologist.
-
The left atrial appendage (LAA) is where 90%+ of AFib-related thrombi form. The Watchman device is a permanent implant that seals off the LAA, providing stroke protection equivalent to anticoagulation. Used for patients with high CHA₂DS₂-VASc but HIGH bleeding risk on anticoagulation. Eligibility: typically CHA₂DS₂-VASc ≥ 2 + relative contraindication to long-term anticoagulation. Procedure-related risks exist; discuss with electrophysiologist.
-
No. Age, sex, risk factors — every input stays in your browser. CHA₂DS₂-VASc computation runs entirely client-side. Open DevTools → Network and confirm zero outbound requests. Safe for personal cardiac-risk analysis.
-
Primary source: Lip GY, Nieuwlaat R, Pisters R, et al. Chest 2010;137:263-272. ESC 2024 AFib Guidelines at escardio.org. AHA/ACC 2023 AFib Guidelines. Friberg et al, Eur Heart J 2012 for the Swedish registry stroke-rate-by-score validation. Janssen + Pfizer + Boehringer Ingelheim publish AFib + DOAC patient education resources.
Related News
You may be interested in these recent stories from our newsroom.
No related news yet for this tool. Our editorial team publishes new pieces every week.
Browse all news →75 more free tools
Calculators, converters, security tools — no signup.